Login / Signup

A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis.

Ida VittrupNiels Steen KroghHenrik Hedegaard Pliess LarsenJesper ElbelingLone SkovKristina Sophie IblerGregor Borut Ernst JemecCharlotte Gotthard MortzRasmus Overgaard BachCarsten Bindslev-JensenMaiken Glud DalagerAlexander EgebergTove AgnerMette DeleuranChristian L VestergaardJacob Pontoppidan Thyssen
Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
While 2-year drug survival was 86%, dupilumab was unable to effectively treat AD in the head-and-neck area, and conjunctivitis was found in 25% of patients.
Keyphrases
  • atopic dermatitis
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • peritoneal dialysis
  • cross sectional
  • drug induced
  • adverse drug
  • preterm birth